Ads
related to: names of bone marrow disease- cGVHD Manifestations
Impacts of Inflammation &
Fibrosis. Learn More Today.
- HCP and Patient Resources
Helpful Resources. Education
and Support. cGVHD Patient Stories.
- Clinical Study Data
Real-World Demographic of Patients.
See Results From a Pivotal Trial.
- Safety Profile
Review Safety Data
From the Clinical Trials.
- cGVHD Manifestations
Search results
Results From The WOW.Com Content Network
Transient myeloproliferative disease, renamed Transient Abnormal Myelopoiesis (TAM), [32] is the abnormal proliferation of a clone of noncancerous megakaryoblasts in the liver and bone marrow.
Myeloma bone disease is due to the overexpression of receptor activator for nuclear factor κ B ligand by bone marrow stroma. RANKL activates osteoclasts , which resorb bone. The resultant bone lesions are lytic (cause breakdown) in nature, and are best seen in plain radiographs, which may show "punched-out" resorptive lesions (including the ...
Bone marrow failure in both children and adults can be either inherited or acquired. Inherited bone marrow failure is often the cause in young children, while older children and adults may acquire the disease later in life. [3] Acquired bone marrow failure may be due to aplastic anemia [4] or myelodysplastic syndrome.
Myelophthisic anemia (also known as myelophthisis) is a severe kind of anemia found in some people with diseases that affect the bone marrow. Myelophthisis is the displacement of hemopoietic bone-marrow tissue into the peripheral blood, [51] either by fibrosis, tumors or granulomas. Neuroacanthocytosis: 29707: D054546
MPNs arise when precursor cells (blast cells) of the myeloid lineages in the bone marrow develop somatic mutations which cause them to grow abnormally. There is a similar category of disease for the lymphoid lineage, the lymphoproliferative disorders acute lymphoblastic leukemia, lymphomas, chronic lymphocytic leukemia and multiple myeloma. [4]
The more aggressive forms of disease require treatment with chemotherapy, radiotherapy, immunotherapy and—in some cases—a bone marrow transplant. The use of rituximab has been established for the treatment of B-cell–derived hematologic malignancies, including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). [7]
The ratio between myeloid series and erythroid cells is relevant to bone marrow function, and also to diseases of the bone marrow and peripheral blood, such as leukemia and anemia. The normal myeloid-to-erythroid ratio is around 3:1; this ratio may increase in myelogenous leukemias , decrease in polycythemias , and reverse in cases of thalassemia .
Smouldering myeloma, however, is not a malignant disease. It is characterised as a pre-malignant disease that lacks symptoms but is associated with bone marrow biopsy showing the presence of an abnormal number of clonal myeloma cells, blood and/or urine containing a myeloma protein, and a significant risk of developing into a malignant disease. [2]